Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Vasoplegic syndrome occurs in 8% to 12% of cases that use cardiopulmonary bypass and carries a high mortality. Although the precise cause of this shock state has yet to determined, it is postulated to be related to abnormal nitric oxide (NO)-mediated dilatation of vascular smooth muscle resulting in arterial and venous vasodilatation. Since its first report in 2014, the off-label use of hydroxocobalmin as a rescue therapy for the treatment of refractory vasodilatory shock has gained attention with a mechanism thought to be primarily mediated by the scavenge, binding to, and prevention of the formation of NO. Importantly, no dose-finding study of hydroxocobalamin for the treatment of vasoplegic shock has been published. Consequently, dosing is extrapolated from the treatment of cyanide toxicity (5 g administered by intravenous infusion over 15 min) and the hemodynamic improvement only appears to persist for a few hours when administered as a bolus. Herein we describe twelve patients with vasoplegic shock following cardiac surgery that received an extended duration infusion of hydroxocobalamin administered over a median of 6 h and illustrate the rapidity and durability of the hemodynamic response encountered. Copyright © 2020 Elsevier Inc. All rights reserved.

Citation

Troy G Seelhammer, Daniel Plack, Scott Nei, Erica Wittwer, James Nelson, Christoph G S Nabzdyk. Extended duration infusion of high-dose hydroxocobalamin for vasoplegic syndrome following cardiac surgery. Heart & lung : the journal of critical care. 2021 Mar-Apr;50(2):173-176

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 33242823

View Full Text